Company intelligence / Profile preview

Ribotech

Moscow, Moscow, Russia

Ownership: Private
Development stage: Other

Overview

Ribotech is a Russian biotechnology company specializing in the development of innovative RNA-based therapeutics, including antisense oligonucleotides and small interfering RNAs (siRNAs). As a subsidiary of the major pharmaceutical group R-Pharm, the company focuses on addressing high-need areas such as infectious diseases and oncology. Its lead candidate, RBT-1, is an antisense oligonucleotide designed to target the Hepatitis C virus by inhibiting viral replication. Headquartered in Moscow and operating within the Skolkovo Innovation Center, Ribotech leverages its proprietary platform to advance a pipeline of precision medicines aimed at viral and malignant targets.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Antisense oligonucleotideSmall interfering RNA
Industry: Biotech

Partnerships

R-PharmSkolkovo Foundation

Beyond the preview

Go deeper on Ribotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribotech.

Explore the full profile